Form 4: Gilead CFO Sells Shares Under 10b5-1 Plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock for $113.57 per share under a pre-arranged trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (GILD), reported a transaction involving the company's common stock.
• On September 15, 2025, Mr. Dickinson disposed of 2,500 shares of common stock at a price of $113.57 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 29, 2024.
• Following this transaction, Mr. Dickinson beneficially owns 159,555 shares of Gilead Sciences common stock directly.

Sentiment

Score: 5

Explanation: The sale of shares by the CFO was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a routine liquidity event for personal financial management rather than a change in sentiment about the company's prospects. This makes the sentiment neutral.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled sale for personal financial management rather than a reaction to new, non-public information.

Negatives

• The sale of shares by a key executive reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May observe a slight decrease in insider ownership, though the pre-planned nature of the sale under a 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The reported transaction is a routine sale of common stock by the Chief Financial Officer under a pre-established Rule 10b5-1 trading plan. Such pre-planned sales are generally for personal financial management and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide new information to alter existing investment theses.

Keywords

Gilead Sciences, GILD, Andrew D. Dickinson, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals